Chairpersons :

R. Gopal, Manohar Chari, N. Sudhakar

Reviewer :

Amit Agarwal

1. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients

(pts) with HER2-negative Metastatic Breast Cancer (MBC) and a germline BRCA

mutation (gBRCAm)

Author: Mark E. Robson

Citation: ASCO ABSTRACT LBA4 Journal of Clinical Oncology 35, no. 15_suppl

2. Final results of a phase 2 study of Talazoparib (TALA) following platinum or multiple

cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2

mutations (ABRAZO)

Author: Nicholas C. Turner

Citation: ASCO Abstract 1007 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)

1007-1007

3. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's

choice of therapy in patients with advanced breast cancer and a germline BRCA

mutation

Author: Litton J.

Citation: SABCS Abstract GS6-07

4. Phase 3 study evaluating efficacy and safety of Veliparib (V) plus Carboplatin (Cb) or

Cb in combination with standard Neoadjuvant Chemotherapy (NAC) in patients (pts)

with early stage Triple-Negative Breast Cancer (TNBC)

Author: Charles E. Geyer

Citation: ASCO ABSTRACT 520 Journal of Clinical Oncology 35, no. 15_suppl (May

2017) 520-520